Lee Chan Henry 4

Accession 0001980648-25-000006

CIK 0001651308other

View on SEC.gov Company Profile

Filed

Dec 11, 7:00 PM ET

Accepted

Dec 12, 4:56 PM ET

Size

29.0 KB

Accession

0001980648-25-000006

Insider Transaction Report

Form 4

Period: 2025-12-10

BeOne Medicines Ltd.ONC

Lee Chan Henry

SVP, General Counsel

Transactions

Exercise/Conversion
American Depositary Shares
2025-12-10$194.47/sh+101$19,641→ 101 total
Exercise/Conversion
American Depositary Shares
2025-12-10$213.32/sh+133$28,372→ 234 total
Exercise/Conversion
American Depositary Shares
2025-12-10$159.03/sh+98$15,585→ 332 total
Sale
American Depositary Shares
2025-12-10$318.28/sh−332$105,669→ 0 total
Exercise/Conversion
American Depositary Shares
2025-12-11$194.47/sh+101$19,641→ 101 total
Exercise/Conversion
American Depositary Shares
2025-12-11$213.32/sh+133$28,372→ 234 total
Exercise/Conversion
American Depositary Shares
2025-12-11$159.03/sh+98$15,585→ 332 total
Sale
American Depositary Shares
2025-12-11$325.00/sh−332$107,900→ 0 total
Exercise/Conversion
Share Option (Right to Buy)
2025-12-10−1,313→ 34,385 total
Exercise: $14.96Exp: 2032-08-04→ Ordinary Shares (1,313 underlying)
Exercise/Conversion
Share Option (Right to Buy)
2025-12-10−1,729→ 102,206 total
Exercise: $16.41Exp: 2033-06-14→ Ordinary Shares (1,729 underlying)
Exercise/Conversion
Share Option (Right to Buy)
2025-12-10−1,274→ 121,940 total
Exercise: $12.23Exp: 2034-06-04→ Ordinary Shares (1,274 underlying)
Exercise/Conversion
Share Option (Right to Buy)
2025-12-11−1,313→ 33,072 total
Exercise: $14.96Exp: 2032-08-04→ Ordinary Shares (1,313 underlying)
Exercise/Conversion
Share Option (Right to Buy)
2025-12-11−1,729→ 100,477 total
Exercise: $16.41Exp: 2033-06-14→ Ordinary Shares (1,729 underlying)
Exercise/Conversion
Share Option (Right to Buy)
2025-12-11−1,274→ 120,666 total
Exercise: $12.23Exp: 2034-06-04→ Ordinary Shares (1,274 underlying)

Holdings

Ordinary Shares
223,106

Footnotes (6)

[F1]Each American Depositary Share represents 13 Ordinary Shares.
[F2]The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.
[F3]The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
[F4]These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
[F5]These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
[F6]These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Documents

1 file

4
wk-form4_1765576578.xmlPrimary
FORM 4

Issuer

BeOne Medicines Ltd.

CIK 0001651308

→

Entity typeother

Related Parties

filerCIK 0001980648

Filing Metadata

Form type: 4
Filed: Dec 11, 7:00 PM ET
Accepted: Dec 12, 4:56 PM ET
Size: 29.0 KB

View on SEC.gov